8-K/A: Xenetic Biosciences Reports Full Year 2024 Financial Results and Highlights DNase-Based Technology Advancements

Xenetic Biosciences announces its full year 2024 financial results, highlighting progress in DNase-based technology for cancer treatment and strategic collaborations.

Summary

• Xenetic Biosciences reported a net loss of approximately $4.0 million for the year ended December 31, 2024.
• Research and development expenses decreased by approximately $0.2 million, or 5.9%, to $3.3 million.
• Royalty payments from Takeda Pharmaceuticals were approximately $2.5 million, relatively flat compared to 2023.
• General and administrative expenses decreased by approximately $0.1 million, or 4.1%, to $3.4 million.
• The company ended the year with approximately $6.2 million in cash.
• Xenetic is focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's progress in its DNase program, strategic collaborations, and cost management. However, the net loss tempers the overall sentiment.

Positives

• Xenetic Biosciences is making progress in advancing its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.
• The company has extended collaborations with the University of Virginia and Scripps Research through 2025.
• Xenetic entered into a Clinical Trial Services Agreement with PeriNess Ltd. to manage investigator-initiated exploratory studies.
• The company ended the year with approximately $6.2 million in cash.
• General and administrative expenses decreased by approximately $0.1 million, or 4.1%, to $3.4 million.

Negatives

• Xenetic Biosciences reported a net loss of approximately $4.0 million for the year ended December 31, 2024.

Risks

• Unexpected costs, charges, or expenses resulting from manufacturing and collaboration agreements could adversely affect the company.
• Failure to realize the anticipated potential of the DNase or PolyXen technologies poses a risk.
• The company's ability to obtain funding and implement its business strategy is subject to uncertainty.
• General market factors, economic conditions, and geopolitical events could adversely affect the company's performance.

Future Outlook

Xenetic is executing on its initiatives as it progresses toward an IND and Phase 1 clinical trial and looks forward to an exciting year.

Management Comments

• Leveraging these relationships allows us to advance our technology toward the clinic while utilizing our resources efficiently and minimizing our internal investment, commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
• Looking ahead to 2025, we are executing on our initiatives as we progress toward an IND and Phase 1 clinical trial and look forward to an exciting year, commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

Industry Context

Xenetic Biosciences is operating in the competitive immuno-oncology space, focusing on innovative technologies to address difficult-to-treat cancers, particularly through its DNase-based approach targeting NETosis.

Comparison to Industry Standards

• It is difficult to compare Xenetic's results to industry standards without knowing the specific stage of development and focus of comparable companies.
• However, companies like BioLineRx, which also focuses on oncology and has partnered with larger pharmaceutical companies, could be considered a peer for comparison.
• The $4.0 million net loss and $6.2 million cash position should be evaluated in the context of Xenetic's burn rate and runway compared to similar biotech companies.

Stakeholder Impact

• Shareholders: The financial results and progress updates provide information for assessing the company's performance and future prospects.
• Employees: The company's focus on advancing its DNase program and strategic collaborations may provide opportunities for professional growth and development.
• Patients: Successful development of the DNase-based technology could lead to new treatment options for difficult-to-treat cancers.

Next Steps

• Progress towards an IND and Phase 1 clinical trial for the DNase-based technology.
• Continued advancement of the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
• Pursuit of other strategic collaborations to advance the company's technology.

Key Dates

Keywords

DNase technology, immuno-oncology, pancreatic carcinoma, clinical trials, financial results, Xenetic Biosciences, XBIO